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Abstract Venous thromboembolism (VTE) is a frequent complication of cancer associated with
morbidity, mortality, increased hospitalizations and higher health care costs. Cancer
patients at increased risk for VTE can be identiﬁed using a validated risk assessment score,
and the incidence of VTE can be reduced in high-risk settings using anticoagulation.
Rivaroxaban is a potent, oral, direct, factor Xa inhibitor approved for the prevention and
treatment of thromboembolic events, including VTE. CASSINI is a double-blind, rando-
mized, parallel-group, multicentre study comparing rivaroxaban with placebo in adult
ambulatory patientswith various cancerswho are initiating systemic cancer therapy andare
at high risk of VTE (Khorana score 2). Patients with primary brain tumours or those at risk
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Introduction
Venous thromboembolism (VTE), which includes deep-vein
thrombosis (DVT) and pulmonary embolism (PE), is a com-
mon, life-threatening condition in many cancer outpatient
populations.1–4 Patients with cancer across most common
tumour types are at a four- to sevenfold greater risk for VTE
compared with individuals without cancer.5,6 The risk of
cancer-associated VTE varies during the course of the disease,
being especially high in the ﬁrst few months after diagnosis
and surgical management, during systemic cancer treatment
and in late-stage metastatic disease.5–8 A recent real-world
retrospective analysis of a health care claims database that
included27,479 solid tumourpatients reported that the rateof
VTE at 3.5 months after the initiation of systemic cancer
therapy was on average 7.3% (range: 4.6–11.6%) and that
the cumulative risk continued to increase to 13.5% (range:
9.8–21.3%) at 12 months.9 The highest rate of VTE was ob-
served among patients receiving systemic cancer therapy for
tumours of the pancreas, stomach or lung.7–10
Development of VTE in patients with cancer is associated
with substantial morbidity and mortality, as well as higher
health care costs.11 Venous thromboembolism is the second
leading cause of death in ambulatory patients with cancer.10
Furthermore, patients with cancer who develop VTE have a
threefold increase in hospitalizations and length of hospital
stay, as well as higher health care costs, compared with
cancer patients without VTE (p < 0.0001).11 The occurrence
of VTE also complicates the clinical management of cancer
and may terminate or delay needed anticancer therapies.
Cancer-associated VTE occurs primarily in the outpatient
setting, whereas major public health efforts to institute
thromboprophylaxis have focused on the inpatient popula-
tion. Previous studies of thromboprophylaxis with low-
molecular-weight heparins (LMWH) in ambulatory patients
with cancer demonstrated that anticoagulation was asso-
ciated with a signiﬁcant relative risk reduction in VTE,
although the absolute beneﬁt was relatively modest, thereby
necessitating prophylactic treatment of a large number of
patients to prevent a single VTE event.12–15 Because the
studies included lower-risk patients and had a relatively
short duration (3 to 4 months), they may not have been
adequate to appropriately assess the value of prophylactic
anticoagulation in outpatients with cancer and higher risk of
VTE. Consequently, current clinical guidelines do not recom-
mend routine outpatient VTE prophylaxis in most ambula-
tory patients with cancer (except for multiple myeloma and
select high-risk solid tumours),1–4 because of the uncer-
tainty regarding the overall beneﬁt-to-risk proﬁle in this
unselected patient population.
Although cancer increases the risk for VTE, individual risk
factors cannot identify high-risk patients for thrombopro-
phylaxis. The Khorana score, which includes multiple risk
factors, was derived and validated in patients initiating
chemotherapy in the outpatient setting. Five risk factors
were identiﬁed that were predictive of chemotherapy-re-
lated VTE (►Table 1).16 This risk score was subsequently
validated in multiple settings and evaluated in more than
12,000 patients17–22 (►Table 2).23–37
Current American Society of Clinical Oncology clinical
practice guidelines and other clinical guidelines recommend
this score as the only validated risk assessment tool for the
prediction of cancer-associated VTE in outpatients.3,4,38,39
The data presented in►Table 2 clearly highlight the high risk
of VTE in patients with cancer and underscore the urgent
need for novel therapies for primary thromboprophylaxis in
this patient population.
10 mg daily or placebo for up to 6 months if there is no evidence of VTE from compression
ultrasonography (CU) during screening or from routine care imagingwithin 30 days prior to
randomization. Mandatory CU will also be performed at weeks 8 and 16 (7 days), and at
study end (3 days). The primary efﬁcacy hypothesis is that anticoagulation with
rivaroxaban reduces the compositeofobjectively conﬁrmed symptomaticor asymptomatic,
lower-extremity,proximal deep-vein thrombosis (DVT); symptomatic,upper-extremityDVT;
symptomatic or incidental pulmonary embolism; and VTE-related death compared with
placebo. The primary safety objective is to assess major bleeding events (Clinical trial
information: NCT02555878).
Table 1 Modiﬁed risk stratiﬁcation model for cancer-associated




Very high risk: stomach, pancreasa
High risk (lung, lymphoma, gynaecologic,
bladder, testicular, renal tumours)
2
1
Pre-chemotherapy platelet count  350,000/μL 1
Haemoglobin level < 10 g/dL or use of red cell
growth factors
1
Pre-chemotherapy leukocyte count > 11,000/μL 1
Body mass index  35 kg/m2 1
Calculate total score, adding points for each criterion in the
modelb
Abbreviation: VTE, venous thromboembolism.
aIn the very high-risk category, primary brain tumours were removed
because patients with known brain tumours are excluded from study
inclusion.
bPatients at high risk for VTE had a baseline risk score 2.
Source: Adapted from Khorana et al.16
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Rivaroxaban is a potent, oral, highly selective, direct
inhibitor of factor Xa. Previous clinical studies demonstrated
that rivaroxaban is effective in VTE prophylaxis in patients
undergoing hip/knee replacement surgery (RECORD 1–4) and
in the treatment and secondary prevention of VTE in patients
with acute symptomatic DVT (EINSTEIN-DVT) or PE
(EINSTEIN-PE), with an acceptable safety proﬁle.40–45 In a
pooled subgroup analysis of EINSTEIN-DVT and EINSTEIN-PE
in patients with a cancer (8% of total population), recurrent
VTE occurred in 5% of patients treatedwith rivaroxaban and in
7% of those receiving enoxaparin plus vitamin K antagonist
(VKA) therapy (hazard ratio [HR]: 0.67; 95% conﬁdence inter-
val [CI]: 0.35–1.30).43,44,46 Additionally, clinically relevant
bleeding occurred in 14% of patients receiving rivaroxaban
and in 16% receiving enoxaparin (HR: 0.80; 95% CI: 0.54–1.20),
andmajorbleeding rateswere2and5%, respectively (HR:0.42;
95% CI: 0.18–0.99). In a recent analysis of a quality improve-
ment initiative to guide rivaroxaban use for cancer-associated
thrombosis, the rates of major bleeding and recurrent VTE
suggested safety and efﬁcacy to be comparable with past-
published experience with LMWH, with the advantage of
reduced patient burden. At 6 months, the cumulative inci-
dence of newor recurrent VTEwas 4.4% (95% CI: 1.4–7.4%) and
major bleeding 2.2% (95% CI: 0–4.2%).47 These preliminary
ﬁndings are suggestive that in the prophylactic setting too,
anticoagulationwith rivaroxaban may reduce the risk for VTE
in patients with cancer, with a favourable safety proﬁle.
The CASSINI study has been designed to evaluate the
efﬁcacy and safety of rivaroxaban versus placebo for primary
thromboprophylaxis in cancer outpatientswho are receiving
systemic cancer therapy and are at high risk for VTE. High-
risk patients will be identiﬁed using the Khorana score.
Methods
Study Design and Setting
CASSINI (NCT02555878) is a phase 3b, randomized, dou-
ble-blind, placebo-controlled, parallel-group, multicentre
study designed to compare the efﬁcacy and safety of
rivaroxaban versus placebo as primary prophylaxis of
Table 2 Summary of clinical evidence highlighting the association between cancer and the risk of venous thromboembolism based
on the Khorana score
Patient population Patients
(N)








Solid tumours or malignant lymphoma23 112 2 y 5.0 15.9 41.4
Any tumour type24 932 NA 13.0 17.1 28.2
Any advanced tumour type25 1,415 2 mo 1.5 4.8 12.9
Any tumour type26 378 113 d 3.0 11.1
Any tumour type27 150 NA 1.9 3.9 9.1





Pancreatic tumours29 108 NA NA 14.0 27.0
Disseminated germ cell tumours30 254 11 y NA NA OR: 11.8; p < 0.001
Prospective studies
Any tumour type31 819 643 d 1.5 (95% CI: 0.6–3.9) Score ¼ 1:
3.8 (95% CI: 1.9–7.4)
Score ¼ 2:
9.6 (95% CI: 6.2–14.7)
17.7
(95% CI: 11.0–27.8)
Any tumour type32 1,097 3 mo NA NA OR: 3.5
(95% CI: 1–12.3)
Any tumour type33 35 3 mo NA NA 23.0
Any tumour type34 580 3 mo 4.0 NA Score  2: 11.0












Non-Hodgkin’s lymphoma36 1,717 NA 2.2 (95% CI: NA) 4.5 (95% CI: 2.3–6.7) 6.6 (95% CI: 2.4–10.8)
p ¼ 0.012
Abbreviations: CI, conﬁdence interval; HR, hazard ratio; NA, not applicable; OR, odds ratio; VTE, venous thromboembolism.
Source: Adapted from Angelini et al.37
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VTE in ambulatory patients who are receiving systemic
cancer treatment and are at an increased risk for VTE. This
study consists of three periods: a 2-week screening period;
a 180-day, double-blind treatment period; and a 30-day,
post-treatment follow-up period (►Fig. 1). The duration of
study participation for each patient is approximately
32 weeks. CASSINI will enrol approximately 700 patients
at 180þ study locations in North America and several
countries in Europe. Patients will provide written informed
consent before initiation of any study-related procedures,
and the study will be conducted in accordance with the
Declaration of Helsinki, Good Clinical Practice, and applic-
able regulatory and country-speciﬁc requirements. This
study will be undertaken at each location only after the
independent ethics committee/institutional review board
(local/central) has given full approval.
Patient Population
Ambulatorymen andwomen, 18 years of age and older, with
various cancer types and a baseline Khorana risk score2, an
expected survival of >6 months, initiating systemic cancer
therapy and who are judged by the investigator as appro-
priate candidates for thromboprophylaxis based on their
clinical status, are eligible for study participation. Patients
with primary brain tumours or those at risk for bleeding are
excluded (►Table 3).
Study Treatment
Patients will be randomized 1:1 to rivaroxaban 10 mg orally
once daily or placebo once daily for 180 (3) days based on a
computer-generated randomization schedule and stratiﬁed
by tumour type (advanced pancreatic cancer [APC] or non-
APC); it is estimated that approximately 25% of the patients
randomly assigned will be those with APC. Study drug is
initiated within  1 week of initiation of systemic cancer
therapy. Study drug can be taken with or without food and
should be taken at the same time each day.
Study drug treatment may be temporarily interrupted or
permanently discontinued as necessary for invasive proce-
dures or as medically needed (e.g., bleeding event or required
prohibited therapy). It is recommended, when possible, that
studydrugbediscontinuedat thediscretionof the investigator
at least 24 hours before an invasive procedure tominimize the
risk of bleeding. Bridgingwith parenteral anticoagulationmay
be considered to balance the risk of bleeding against that of
VTE. Study drug should be restarted after surgical or other
invasive procedures as soon as adequatehaemostasis has been
established (generally 24 hours for low-risk bleeding or minor
surgical procedures and 48 hours for high-risk bleeding or
major surgical procedures).
If the platelet count decreases to <25  109/L for more
than 1 week, then the patient will be temporarily discon-




• ECOG performance status
 of 0-2
• Khorana thromboembolic
 risk score ≥2
Day 1
Rivaroxaban
















Day 180 Day 210
Fig. 1 CASSINI study design. ECOG, Eastern Cooperative Oncology Group.
Table 3 Major inclusion and exclusion criteria for patient selection
Inclusion criteria Exclusion criteria
1. 18 y of age 1. Diagnosis of primary brain tumour
2. Histologically conﬁrmed solid malignancy including, but
not limited to, pancreas, lung, stomach, colon, rectum,
bladder, breast, ovary, renal or lymphoma (haematologic),
with locally advanced or metastatic disease
2. Known history of brain metastases
3. ECOG PS 0–2 3. Haematologic malignancies with the exception of
lymphoma
4. Khorana score 2 4. Bleeding diathesis, haemorrhagic lesions, active bleeding
and other conditions with a high risk for bleeding
5. Adequate renal function: CrCl  30 mL/min 5. Life expectancy of ≤6 mo
6. Plan to initiate systemic cancer therapy within  1 wk of
receiving ﬁrst dose of study drug with the intent of
continuing systemic cancer therapy with study drug during
the double-blind treatment period
6. Evidence of VTE on screening CU or incidental VTE
identiﬁed on spiral CT scans ordered primarily for staging
or restaging of malignancy ≤30 d prior to randomization
Abbreviations: CrCl, creatinine clearance; CT, computed tomography; CU, compression ultrasonography; ECOG, Eastern Cooperative Oncology
Group; PS, performance status; VTE, venous thromboembolism.
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Patients should have their platelet count monitored carefully
if the platelet count decreases to <50  109/L, and investi-
gator discretion should be used. Patients should have their
renal function monitored when creatinine clearance (CrCl)
drops below <30 mL/min and investigator discretion should
be used with regard to study drug administration. If the
patient’s CrCl decreases to <15 mL/min, then the patient
should be discontinued from study drug treatment.
Study Endpoints
The primary efﬁcacy composite endpoint is the time from
randomization to the ﬁrst occurrence of objectively con-
ﬁrmed, symptomatic, lower-extremity, proximal DVT;
asymptomatic, lower-extremity, proximal DVT; sympto-
matic, upper-extremity DVT; symptomatic, non-fatal PE;
incidental PE; or VTE-related death during the 180-day
(3 days), double-blind treatment period as adjudicated
by an independent blinded clinical endpoint committee
(CEC; ►Table 4). Key secondary efﬁcacy endpoints include
symptomatic VTE events (DVT/PE), VTE-related deaths or
all-cause mortality. Other secondary efﬁcacy endpoints
include time from randomization to the ﬁrst occurrence
of the individual components of the composite primary
efﬁcacy endpoint, symptomatic distal DVT, conﬁrmed
fatal/non-fatal arterial thromboembolism (ATE) events
and conﬁrmed fatal/non-fatal visceral VTE events. In ad-
dition, a composite of symptomatic, lower-extremity,
proximal DVT; asymptomatic, lower-extremity, proximal
DVT; symptomatic, upper-extremity DVT; non-fatal PE;
incidental PE; and all-cause mortality will be assessed.
The primary safety endpoint is the time to a major
bleeding event as deﬁned by the International Society on
Thrombosis and Haemostasis (ISTH). Bleeding events will be
classiﬁed using protocol-speciﬁed deﬁnitions for major,
clinically relevant non-major or minor bleeding. Secondary
safety endpoints include percentages of clinically relevant
non-major bleeding, minor bleeding and any bleeding.
Exploratory endpoints include biomarkers related to
inﬂammation and hypercoagulability (including D-dimer,
P-selectin and tissue factor), pharmacokinetics and expo-
sure response to rivaroxaban and health care resource
utilization.
Study Procedures
At the screening visit (day 14 to 1), bilateral, lower-
extremity, venous duplex compression ultrasonography
(CU) will be performed (►Table 5). Patients with baseline
DVT on screening CU or incidental DVT or PE identiﬁed
during routine care imaging (e.g., spiral computed tomogra-
phy [CT] scans used primarily for staging or restaging of
malignancy) within 30 days prior to randomization will not
be eligible for randomization.
Studyvisitswilloccuratweek8(7days),week16(7days)
and day 180/end of treatment (EOT; 3 days) during the
double-blind treatment period. Mandatory CU will be per-
formed at each visit. After a 30-day post-treatment follow-up
period, all patients, including those who discontinued study
drug before day 180 (3 days), will be contacted for a day 210
(7 days)/end-of-study (EOS) follow-up visit. Vital status (i.e.,
dead, alive or lost to follow-up) as well as clinical status review
Table 4 CASSINI study endpoints
Efficacy
Primary • Composite of time from randomization to ﬁrst occurrence of symptomatic, lower-extremity, proximal DVT;
asymptomatic, lower-extremity, proximal DVT; symptomatic, upper-extremity DVT; symptomatic, nonfatal
PE; incidental PE; or VTE-related death during the 180-d (3 d), double-blind treatment period
Key
secondary
• Symptomatic VTE events
• VTE-related deaths
• All-cause mortality
Other • Time from randomization to ﬁrst occurrence of individual components of the composite primary efﬁcacy
endpoint
• Conﬁrmed fatal/non-fatal arterial thromboembolism events
• Conﬁrmed fatal/non-fatal visceral VTE events
• Composite of symptomatic, lower-extremity, proximal DVT; asymptomatic, lower-extremity, proximal DVT;
symptomatic, upper-extremity DVT; symptomatic, non-fatal PE; incidental PE; and all-cause mortality
Safety
Primary • Time to a major bleeding event as deﬁned by the ISTH
Secondary • Percentages of clinically relevant non-major bleeding, minor bleeding and any bleeding
Exploratory
• Inﬂammation and hypercoagulability biomarkers (e.g., D-dimer, P-selectin and tissue factor)
• Pharmacokinetics and exposure response to rivaroxaban
• Health care resource utilization
Abbreviations: DVT, deep-vein thrombosis; ISTH, International Society on Thrombosis and Haemostasis; PE, pulmonary embolism; VTE, venous
thromboembolism.
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for suspected outcome and safety bleeding events will be
completed. Adverse events (AEs) and concomitant medications
will be collected.
Blood samples will be collected at screening, weeks 8 and
16, and day 180/EOT to measure levels of circulating D-dimer,
P-selectin and tissue factor.
Study Oversight
A steering committeehas been formed that has overall respon-
sibility for the conduct and reporting of the study. Suspected
DVT and non-fatal PE occurring during the double-blind treat-
ment phase and the 30-day follow-up phase will be centrally
adjudicated by an independent, blinded CEC. Additionally,
incidental DVT or PE, identiﬁed from routine care imaging
during the same time period, will be adjudicated as asympto-
matic DVTor PE events. Finally, any clinical event that suggests
the possibility that a major or clinically relevant non-major
bleeding event has occurred will be sent for adjudication. An
Independent Data Monitoring Committee (IDMC) will ensure
that patient safety is not compromised.
Sample Size and Statistical Analyses
Although estimates of VTE event rates vary, most previous
clinical studies,whichwere generally between3and4months
in duration, reported relative risk reductions between 50 and
64% when ambulatory patients receiving systemic cancer
therapy were also treated with anticoagulant therapy.48 Esti-
mates of assumed VTE events are derived from the Vienna
CATS (Cancer and Thrombosis Study) group, which used the
Khorana score to monitor 819 ambulatory patients with
Table 5 Schedule of assessments
Period Screening Double-blind treatment Post-treatment
(follow-up)






Month – 2 4 6 7









Relevant medical history X
Disease staging
(using TNM system









(PT, aPTT and INR)
X







Contact IWRS for study
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cancer for symptomatic VTE.31 The Kaplan–Meier analysis
demonstrated that the cumulative probability of VTE after
6 months was 17.7% (95% CI: 11.0–27.8%; N ¼ 93) in patients
with a Khorana score 3 and 9.6% (95% CI: 6.2–14.7%;
N ¼ 221) in patients with a Khorana score of 2.31 Taken
together, these results and those of smaller randomized con-
trolled trials support a projected symptomatic event rate at
180 days of at least 9.5%. Adjudication of asymptomatic
proximal DVT and incidental PE is estimated to add 5 to 8%,
supporting a 14.5% incidence rate in the placebo group.
Assuming a cumulative incidence rate of 14.5% in the
placebo group and 6.0% in the rivaroxaban group for the
primary composite endpoint, a total of approximately 700
patients will be required to demonstrate an approximately
60% relative risk reduction in the primary efﬁcacy endpoint
with a two-sided, type 1 error rate of 5%, >90% statistical
power and assuming a 20% discontinuation rate.
The CASSINI study will evaluate the hypothesis that
prophylaxis with rivaroxaban will be superior to placebo
for the composite primary efﬁcacy endpoint. The primary
and key secondary efﬁcacy endpoint analyses will be based
on the intent-to-treat population, which consists of all
randomized patients with valid informed consent. All safety
endpoints will be analysed using the safety analysis set,
which consists of all randomized patients who receive at
least one dose of study drug.
The primary composite endpoint and key secondary efﬁ-
cacy endpoint analyses will be performed on a time-to-ﬁrst-
event basis, using a stratiﬁed Cox proportional hazardmodel
and treatment group as a categorical variable. Patients who
have no primary efﬁcacy events during the double-blind
treatment period, who are lost to follow-up, who die because
of non–VTE-related reasons or who withdraw informed
consent before the EOT will be censored. To account for
Table 5 (Continued)
Period Screening Double-blind treatment Post-treatment
(follow-up)







Urine pregnancy test X X
Record vital signs
including weight
X X X X X
Record ECOG
performance status
X X X X X
Record central venous
catheter status




X X X X




X X X X
Adverse events X X X X X X






X X X X
Clinical events relevant
to efﬁcacy endpoints





Biomarker sample X X X X
Pharmacokinetic sample X
Abbreviations: aPTT, activatedpartial thromboplastin time;BMI, bodymass index; ECOG,EasternCooperativeOncologyGroup; eGFR, estimatedglomerular
ﬁltration rate; INR, international normalised ratio; IWRS, interactive web response system; PT, prothrombin time; TNM, tumour, node, metastasis.
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competing risks (i.e., deaths from causes other than VTE for
efﬁcacy or fatal bleeding for safety), a cumulative incidence
approach using Gray’s two-sample test (two-sided, type 1
error rate of 5%) will be adopted. Associated HR and 95% CI
will be calculated using a Fine and Gray regression model.
Kaplan–Meier estimates adjusted for competing risk over
time will be plotted for time-to-event variables.
Statistical comparison of the primary safety endpoint will
be performed using a Cox proportional hazards model with
treatment as a covariate. Additionally, the frequency of
bleeding events in each treatment group will be summar-
ized. Secondary safety endpoints including AEs and labora-
tory events will also be summarized.
Discussion
CASSINI will be the ﬁrst randomized clinical study to compare
the efﬁcacyand safetyof rivaroxaban, an oral anticoagulant that
has undergone rigorous investigation, with placebo in the
prevention of VTE in high-risk, ambulatory patientswith cancer
receiving systemic cancer therapy. At present, no other antic-
oagulant is approved for primary thromboprophylaxis in out-
patientswith cancer, and inclusion of a placebo armwill allowa
clear determination of the clinical value of rivaroxaban in this
setting. Importantly, CASSINI will enrol only patients with
cancer who are at increased risk of VTE, as determined by the
previously validated Khorana risk score. This approach is con-
sistent with the 2013 and 2014 American Society of Clinical
Oncology VTE guidelines, which recommend the use of this risk
score rather than individual risk factors to identify patients at
increased risk.3,38
Patients with primary brain tumours are excluded from
CASSINI because of an increased risk of intracranial bleeding
demonstrated in a prior prophylaxis study. The PRODIGE
study (NCT00135876) demonstrated that dalteparin LMWH
thromboprophylaxis was associated with a higher rate of
intracranial bleeding compared with placebo in patients
with newly diagnosed malignant glioma (5.1 vs. 1.2% at 12
months).49 Although this is an area requiring additional
investigation, given the known higher rates of bleeding, we
believe that this issue is best addressed in a separate, speciﬁc
study and have chosen to exclude patients with brain tu-
mours from the CASSINI trial.
Supportive evidence from previous studies suggests that
rivaroxaban 10 mg daily may be appropriate for effective VTE
prevention in high-risk settings. Venous thromboembolism
prophylaxis studies in patients undergoing knee or hip repla-
cement surgery demonstrated that rivaroxaban 10 mg daily
provides an absolute reduction in VTE risk ranging from 2.6 to
9.2% and has an acceptable safety proﬁle.40–42 Data from the
EINSTEIN sub-studiesprovide someexperiencewith theuseof
rivaroxaban 15 to 20 mg in patients with cancer in the treat-
ment or secondary prophylaxis settings.43,44,46,50 Clinically
relevant bleeding in patients treated with rivaroxaban 15 to
20 mg was similar to the rate reported in the enoxaparin/VKA
antagonist group, and there were signiﬁcantly fewer major
bleeding events in the rivaroxaban treatment group.43,44,46 A
recent quality assurance initiative to guide rivaroxaban use in
cancer-associated thrombosis also suggested efﬁcacy/safety
proﬁle to be at least non-inferior to LMWH, with the added
beneﬁt of reduced patient burden.47
The duration of previous primary VTE prophylaxis studies
was generally between 3 and 4 months. However, given the
cumulative nature of VTE risk in patients with cancer receiv-
ing chemotherapy,9 the risk of VTE persists beyond this
initial time period. The use of a once-daily oral agent allows
a patient-friendly approach to extending the period of pro-
phylaxis than has been previously studied. CASSINI was
designed to extend the observation window to 6 months
after initiation of a new systemic cancer regimen to evaluate
whether rivaroxaban can effectively and safely prevent VTE
events in patients who typically undergo several cycles of
systemic cancer therapy. This approach will allow for a more
conﬁdent assessment of the beneﬁt–risk proﬁle of rivarox-
aban thromboprophylaxis in this population.
Perioperative management of patients who require an
elective surgical or other invasive procedure is an area of
ongoing uncertainty. There is a lack of data speciﬁcally in the
high-risk cancer population. Current clinical guidelines from
the American Heart Association, the American College of
Cardiology, theHeartRhythmSocietyandtheAmericanCollege
of Chest Physicians recommend that patients at highest risk for
thromboembolismwithout excessive bleeding risk should con-
sider bridging.51,52 Thus, bridging anticoagulation may be
considered in CASSINI, which is enrolling cancer patients at
high risk for VTE, in accordance with these recommendations.
In the CASSINI study, DVTwill be diagnosed using CU, the
standardmethod for the diagnosis of this condition because of
its low level of invasiveness and high sensitivity.53 A prospec-
tive cohort study of patients undergoing total hip or knee
arthroplasty indicated that CU has a positive predictive value
(71 vs. 25% for clinical examination) and sensitivity (83 vs. 11%
for clinical examination).54 The Joint American Academy of
Family Physicians/American College of Physicians Panel on
DVT/PE recommends theuse of CU for patientswith at least an
intermediate probability of lower-extremity DVT.55
An important feature of the CASSINI study is the use of
screening to detect asymptomatic VTE, which is relatively
common and is associated with higher mortality similarly to
patientswith symptomatic VTE. An analysis of 1,151 radiologic
examinationsof135APCpatientsdemonstrated that incidental
events comprised 33.3% of PEs, 21.4% of DVTs and 100% of
visceral VTEs. Deep-vein thrombosis (HR: 25; 95% CI: 10–63;
p < 0.0001), PE (HR: 8.9; 95% CI: 2.5–31.7; p ¼ 0.007) and
visceral events (HR: 2.6; 95% CI: 1.6–4.2; p ¼ 0.0001) were all
independently associatedwithmortality. Therewas no signiﬁ-
cant difference between asymptomatic and symptomatic
events in terms of conditional survival at 3 or 6 months after
diagnosis.56 Consistent with the documented correlation be-
tween asymptomatic VTE andhighermortality, theU.S. andEU
(European Union) regulatory authorities accept the use of
asymptomatic VTE as a relevant endpoint in registrational
studies.
CASSINI is part of CALLISTO, a new global research pro-
gramme that will evaluate rivaroxaban across the spectrum
of prevention and treatment of cancer-associated VTE.
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CALLISTO will involve more than 4,000 patients worldwide
and will comprise nine initiatives, including several clinical
studies, registries, a survey and expert guidance.57 The
CASSINI study will provide the ﬁrst data related to the use
of longer-term, oral anticoagulation for the primary preven-
tion of VTE in high-risk, ambulatory patients with cancer
who are receiving systemic cancer therapy. The only other
primary VTE prevention study is the phase 2 AVERT study
(NCT02048865), which will evaluate the efﬁcacy and safety
of the oral anticoagulant apixaban for the prevention of VTE
in high-risk ambulatory patients with cancer. Treatment
with an effective and well-tolerated oral anticoagulant,
administered once daily, has the potential to reduce the
burden of VTE and its consequences for patients with cancer.
What is known about this topic?
• Patients with cancer are at a four- to sevenfold greater
risk for venous thromboembolism (VTE) comparedwith
individualswithoutcancer. The riskdiffers amongcancer
patients, and the Khorana risk score allows for identiﬁ-
cation of patients with cancer at increased risk for VTE.
• Cancer-associated VTE occurs primarily in the out-
patient setting, and VTE is the second leading cause
of death in ambulatory patients with cancer.
• Previous studies of thromboprophylaxis with LMWH
(low-molecular-weight heparins) in ambulatory pa-
tients with cancer have demonstrated that anticoagu-
lation is associated with a signiﬁcant relative risk
reduction in VTE, but current clinical guidelines do
not recommend routine outpatient VTE prophylaxis
because the overall beneﬁt-to-risk proﬁle in an un-
selected patient population is uncertain. At present, no
anticoagulant is approved for primary thrombopro-
phylaxis in outpatients with cancer.
What does this paper add?
• The CASSINI trial will be the ﬁrst randomized clinical
study designed to evaluate the efﬁcacy and safety of
rivaroxaban, an oral anticoagulant, versus placebo for
prevention of VTE in high-risk, ambulatory patients
with cancer receiving systemic cancer therapy.
• It will provide theﬁrst data related to the use of longer-
term, oral anticoagulation for the primary prevention
of VTE in this setting.
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